General form of registration statement for all companies including face-amount certificate companies

JANUARY AND MARCH 2012 FINANCING (Details Textual)

v2.4.0.8
JANUARY AND MARCH 2012 FINANCING (Details Textual) (USD $)
3 Months Ended 12 Months Ended 67 Months Ended 70 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Mar. 31, 2013
Debt Conversion, Converted Instrument, Shares Issued (in shares)       199,250    
Entity's Volume Weighted Average Price     $ 34.60      
Warrants Exercise Terms and Expiration Description     In the event that the Company's average daily volume weighted average price was at or above $15.00 during the Measuring Period, the Class B Warrants were to expire unexercised. The Announcement Date was the earlier of (1) the date on which the Company announces via press release the results of the pharmacokinetic study of its TNX-102 drug formulation; or (2) June 1, 2012. On April 5, 2012 the Company issued a press release announcing the results of the pharmacokinetic study of its TNX-102 drug formulation, which is defined as an Announcement Date for the purpose of the Class B Warrants. Based on the Company's average daily volume weighted average price, which was $34.60 per share, during the Measuring Period, the Class B Warrants expired unexercised.      
Change in fair value of warrant liability $ 0 $ (47,023) $ 1,177,026   $ 1,177,026 $ 1,177,026
Warrants Issued During Period To Purchase Common Stock 10,800   1,538      
Percentage Of Shares Issuable Upon Excercise Of Warrants       33.00%    
Stock Units Issued Upon Conversion Of Convertible Debt Purchase Price     25,000      
Warrants reclassified to equity upon expiry of reset provisions 0 0 3,938,946 0 3,938,946 3,938,946
Warrants Exercise Price (in dollars per share) $ 12.00   $ 20.00      
Common Stock [Member]
           
Number Of Shares Included In One Stock Unit (in shares)     1,250      
Warrant [Member]
           
Valuation Assumptions Issuance Date 1     Jan. 20, 2012      
Valuation Assumptions Issuance Date 2     Mar. 01, 2012      
Valuation Assumptions Expiration Date     Jun. 06, 2012      
Additional Paid-In Capital [Member]
           
Warrants reclassified to equity upon expiry of reset provisions     3,938,946      
Placement Agents [Member]
           
Financing Arrangements Expense     706,511      
Placement Agents [Member] | Other Financing Cost [Member]
           
Financing Arrangements Expense     270,798      
Placement Agents [Member] | Additional Paid-In Capital [Member]
           
Financing Arrangements Expense     435,713      
Minimum [Member]
           
Percentage Of Investor Fee Payable Under Registration Rights Agreement     1.00%      
Maximum [Member]
           
Percentage Of Investor Fee Payable Under Registration Rights Agreement     10.00%      
Class A Warrant [Member]
           
Debt Conversion, Converted Instrument, Shares Issued (in shares)     1,250      
Class B Warrant [Member]
           
Debt Conversion, Converted Instrument, Shares Issued (in shares)     1,250      
Entity Minimum Volume Weighted Average Price Effect On Exercise Warrants     $ 15.00      
January 2012 Financing [Member]
           
Stock Units Issued During Period     172.118      
Proceeds From Issuance Of Stock Units     2,377,950      
Proceeds From Conversion Of Convertible Debentures     1,925,000      
Warrants Issued During Period To Purchase Common Stock     215,148      
January 2012 Financing [Member] | Placement Agents [Member]
           
Warrants Issued During Period To Purchase Common Stock     11,765      
March 2012 Financing [Member]
           
Stock Units Issued During Period     92.5926      
Proceeds From Issuance Of Stock Units     2,314,815      
Warrants Issued During Period To Purchase Common Stock     115,741      
March 2012 Financing [Member] | Placement Agents [Member]
           
Warrants Issued During Period To Purchase Common Stock     11,574      
Financing Arrangements [Member]
           
Warrants Exercise Period     7 years      
Percentage Of Shares Issuable Upon Excercise Of Warrants     10.00%      
Warrants Exercise Price (in dollars per share)     $ 25.00      
Financing Arrangements [Member] | Placement Agents [Member]
           
Payment For Commission     466,777      
Percentage Of Commission Paid     8.00%      
Percentage Of Non Accountable Expenses     2.00%      
Warrants Issued During Period To Purchase Common Stock     23,339      
Financing Arrangements [Member] | Class A Warrant [Member]
           
Warrants Not Settleable In Cash Fair Value Disclosure     2,549,684   2,549,684  
Warrants Exercise Price (in dollars per share)     $ 25.00      
Financing Arrangements [Member] | Agent Warrants [Member]
           
Warrants Not Settleable In Cash Fair Value Disclosure     $ 212,235   $ 212,235